Gilead is next into target degradation
After opting in last year, Gilead picks up Kymera's KT-200.
Revealed: Merck’s double bet on TROP2
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Fuelled by Pfizer, Triana enters the clinic
The industry’s first ALK degrader starts its first human study.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
